IL
Illinois House Bill HB2046

Illinois 2023-2024 Regular Session

Illinois House Bill HB2046 Compare Versions

Only one version of the bill is available at this time.
OldNewDifferences
11 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB2046 Introduced , by Rep. Kelly M. Cassidy SYNOPSIS AS INTRODUCED: 720 ILCS 570/315.7 new 720 ILCS 570/318 Amends the Illinois Controlled Substances Act. Provides that all decisions regarding the treatment of patients experiencing pain, including chronic pain, shall be made by the prescriber. Provides that ordering, prescribing, dispensing, administering, or paying for controlled substances, including opioids, shall not in any way be predetermined by specific morphine milligram equivalent guidelines. Provides that, before the Department of Human Services releases confidential information from the central repository, the applicant, in addition to other requirements of the Act, must demonstrate in writing to the Department that the applicant has a valid court order or subpoena for the release of the confidential information requested. LRB103 05014 RLC 51034 b A BILL FOR 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB2046 Introduced , by Rep. Kelly M. Cassidy SYNOPSIS AS INTRODUCED: 720 ILCS 570/315.7 new 720 ILCS 570/318 720 ILCS 570/315.7 new 720 ILCS 570/318 Amends the Illinois Controlled Substances Act. Provides that all decisions regarding the treatment of patients experiencing pain, including chronic pain, shall be made by the prescriber. Provides that ordering, prescribing, dispensing, administering, or paying for controlled substances, including opioids, shall not in any way be predetermined by specific morphine milligram equivalent guidelines. Provides that, before the Department of Human Services releases confidential information from the central repository, the applicant, in addition to other requirements of the Act, must demonstrate in writing to the Department that the applicant has a valid court order or subpoena for the release of the confidential information requested. LRB103 05014 RLC 51034 b LRB103 05014 RLC 51034 b A BILL FOR
22 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB2046 Introduced , by Rep. Kelly M. Cassidy SYNOPSIS AS INTRODUCED:
33 720 ILCS 570/315.7 new 720 ILCS 570/318 720 ILCS 570/315.7 new 720 ILCS 570/318
44 720 ILCS 570/315.7 new
55 720 ILCS 570/318
66 Amends the Illinois Controlled Substances Act. Provides that all decisions regarding the treatment of patients experiencing pain, including chronic pain, shall be made by the prescriber. Provides that ordering, prescribing, dispensing, administering, or paying for controlled substances, including opioids, shall not in any way be predetermined by specific morphine milligram equivalent guidelines. Provides that, before the Department of Human Services releases confidential information from the central repository, the applicant, in addition to other requirements of the Act, must demonstrate in writing to the Department that the applicant has a valid court order or subpoena for the release of the confidential information requested.
77 LRB103 05014 RLC 51034 b LRB103 05014 RLC 51034 b
88 LRB103 05014 RLC 51034 b
99 A BILL FOR
1010 HB2046LRB103 05014 RLC 51034 b HB2046 LRB103 05014 RLC 51034 b
1111 HB2046 LRB103 05014 RLC 51034 b
1212 1 AN ACT concerning criminal law.
1313 2 Be it enacted by the People of the State of Illinois,
1414 3 represented in the General Assembly:
1515 4 Section 5. The Illinois Controlled Substances Act is
1616 5 amended by changing Section 318 and by adding Section 315.7 as
1717 6 follows:
1818 7 (720 ILCS 570/315.7 new)
1919 8 Sec. 315.7. Chronic pain treatment.
2020 9 (a) In this Section, "opioid" means a narcotic drug or
2121 10 substance that is a Schedule II controlled substance under
2222 11 paragraph (1), (2), (3), or (5) of subsection (b) or under
2323 12 subsection (c) of Section 206.
2424 13 (b) All decisions regarding the treatment of patients
2525 14 experiencing pain, including chronic pain, shall be made by
2626 15 the prescriber.
2727 16 (c) Ordering, prescribing, dispensing, administering, or
2828 17 paying for controlled substances, including opioids, shall not
2929 18 in any way be predetermined by specific morphine milligram
3030 19 equivalent guidelines.
3131 20 (720 ILCS 570/318)
3232 21 Sec. 318. Confidentiality of information.
3333 22 (a) Information received by the central repository under
3434
3535
3636
3737 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB2046 Introduced , by Rep. Kelly M. Cassidy SYNOPSIS AS INTRODUCED:
3838 720 ILCS 570/315.7 new 720 ILCS 570/318 720 ILCS 570/315.7 new 720 ILCS 570/318
3939 720 ILCS 570/315.7 new
4040 720 ILCS 570/318
4141 Amends the Illinois Controlled Substances Act. Provides that all decisions regarding the treatment of patients experiencing pain, including chronic pain, shall be made by the prescriber. Provides that ordering, prescribing, dispensing, administering, or paying for controlled substances, including opioids, shall not in any way be predetermined by specific morphine milligram equivalent guidelines. Provides that, before the Department of Human Services releases confidential information from the central repository, the applicant, in addition to other requirements of the Act, must demonstrate in writing to the Department that the applicant has a valid court order or subpoena for the release of the confidential information requested.
4242 LRB103 05014 RLC 51034 b LRB103 05014 RLC 51034 b
4343 LRB103 05014 RLC 51034 b
4444 A BILL FOR
4545
4646
4747
4848
4949
5050 720 ILCS 570/315.7 new
5151 720 ILCS 570/318
5252
5353
5454
5555 LRB103 05014 RLC 51034 b
5656
5757
5858
5959
6060
6161
6262
6363
6464
6565 HB2046 LRB103 05014 RLC 51034 b
6666
6767
6868 HB2046- 2 -LRB103 05014 RLC 51034 b HB2046 - 2 - LRB103 05014 RLC 51034 b
6969 HB2046 - 2 - LRB103 05014 RLC 51034 b
7070 1 Section 316 and former Section 321 is confidential.
7171 2 (a-1) To ensure the federal Health Insurance Portability
7272 3 and Accountability Act and confidentiality of substance use
7373 4 disorder patient records rules that mandate the privacy of an
7474 5 individual's prescription data reported to the Prescription
7575 6 Monitoring Program received from a retail dispenser under this
7676 7 Act, and in order to execute the duties and responsibilities
7777 8 under Section 316 of this Act and rules for disclosure under
7878 9 this Section, the Clinical Director of the Prescription
7979 10 Monitoring Program or his or her designee shall maintain
8080 11 direct access to all Prescription Monitoring Program data. Any
8181 12 request for Prescription Monitoring Program data from any
8282 13 other department or agency must be approved in writing by the
8383 14 Clinical Director of the Prescription Monitoring Program or
8484 15 his or her designee unless otherwise permitted by law.
8585 16 Prescription Monitoring Program data shall only be disclosed
8686 17 as permitted by law.
8787 18 (a-2) As an active step to address the current opioid
8888 19 crisis in this State and to prevent and reduce addiction
8989 20 resulting from a sports injury or an accident, the
9090 21 Prescription Monitoring Program and the Department of Public
9191 22 Health shall coordinate a continuous review of the
9292 23 Prescription Monitoring Program and the Department of Public
9393 24 Health data to determine if a patient may be at risk of opioid
9494 25 addiction. Each patient discharged from any medical facility
9595 26 with an International Classification of Disease, 10th edition
9696
9797
9898
9999
100100
101101 HB2046 - 2 - LRB103 05014 RLC 51034 b
102102
103103
104104 HB2046- 3 -LRB103 05014 RLC 51034 b HB2046 - 3 - LRB103 05014 RLC 51034 b
105105 HB2046 - 3 - LRB103 05014 RLC 51034 b
106106 1 code related to a sport or accident injury shall be subject to
107107 2 the data review. If the discharged patient is dispensed a
108108 3 controlled substance, the Prescription Monitoring Program
109109 4 shall alert the patient's prescriber as to the addiction risk
110110 5 and urge each to follow the Centers for Disease Control and
111111 6 Prevention guidelines or his or her respective profession's
112112 7 treatment guidelines related to the patient's injury. This
113113 8 subsection (a-2), other than this sentence, is inoperative on
114114 9 or after January 1, 2024.
115115 10 (b) The Department must carry out a program to protect the
116116 11 confidentiality of the information described in subsection
117117 12 (a). The Department may disclose the information to another
118118 13 person only under subsection (c), (d), or (f) and may charge a
119119 14 fee not to exceed the actual cost of furnishing the
120120 15 information.
121121 16 (c) The Department may disclose confidential information
122122 17 described in subsection (a) to any person who is engaged in
123123 18 receiving, processing, or storing the information.
124124 19 (d) The Department may release confidential information
125125 20 described in subsection (a) to the following persons:
126126 21 (1) A governing body that licenses practitioners and
127127 22 is engaged in an investigation, an adjudication, or a
128128 23 prosecution of a violation under any State or federal law
129129 24 that involves a controlled substance.
130130 25 (2) An investigator for the Consumer Protection
131131 26 Division of the office of the Attorney General, a
132132
133133
134134
135135
136136
137137 HB2046 - 3 - LRB103 05014 RLC 51034 b
138138
139139
140140 HB2046- 4 -LRB103 05014 RLC 51034 b HB2046 - 4 - LRB103 05014 RLC 51034 b
141141 HB2046 - 4 - LRB103 05014 RLC 51034 b
142142 1 prosecuting attorney, the Attorney General, a deputy
143143 2 Attorney General, or an investigator from the office of
144144 3 the Attorney General, who is engaged in any of the
145145 4 following activities involving controlled substances:
146146 5 (A) an investigation;
147147 6 (B) an adjudication; or
148148 7 (C) a prosecution of a violation under any State
149149 8 or federal law that involves a controlled substance.
150150 9 (3) A law enforcement officer who is:
151151 10 (A) authorized by the Illinois State Police or the
152152 11 office of a county sheriff or State's Attorney or
153153 12 municipal police department of Illinois to receive
154154 13 information of the type requested for the purpose of
155155 14 investigations involving controlled substances; or
156156 15 (B) approved by the Department to receive
157157 16 information of the type requested for the purpose of
158158 17 investigations involving controlled substances; and
159159 18 (C) engaged in the investigation or prosecution of
160160 19 a violation under any State or federal law that
161161 20 involves a controlled substance.
162162 21 (4) Select representatives of the Department of
163163 22 Children and Family Services through the indirect online
164164 23 request process. Access shall be established by an
165165 24 intergovernmental agreement between the Department of
166166 25 Children and Family Services and the Department of Human
167167 26 Services.
168168
169169
170170
171171
172172
173173 HB2046 - 4 - LRB103 05014 RLC 51034 b
174174
175175
176176 HB2046- 5 -LRB103 05014 RLC 51034 b HB2046 - 5 - LRB103 05014 RLC 51034 b
177177 HB2046 - 5 - LRB103 05014 RLC 51034 b
178178 1 (e) Before the Department releases confidential
179179 2 information under subsection (d), the applicant must
180180 3 demonstrate in writing to the Department that:
181181 4 (1) the applicant has reason to believe that a
182182 5 violation under any State or federal law that involves a
183183 6 controlled substance has occurred; and
184184 7 (2) the requested information is reasonably related to
185185 8 the investigation, adjudication, or prosecution of the
186186 9 violation described in subdivision (1); and
187187 10 (3) the applicant has a valid court order or subpoena
188188 11 for the release of the confidential information requested.
189189 12 (f) The Department may receive and release prescription
190190 13 record information under Section 316 and former Section 321
191191 14 to:
192192 15 (1) a governing body that licenses practitioners;
193193 16 (2) an investigator for the Consumer Protection
194194 17 Division of the office of the Attorney General, a
195195 18 prosecuting attorney, the Attorney General, a deputy
196196 19 Attorney General, or an investigator from the office of
197197 20 the Attorney General;
198198 21 (3) any Illinois law enforcement officer who is:
199199 22 (A) authorized to receive the type of information
200200 23 released; and
201201 24 (B) approved by the Department to receive the type
202202 25 of information released; or
203203 26 (4) prescription monitoring entities in other states
204204
205205
206206
207207
208208
209209 HB2046 - 5 - LRB103 05014 RLC 51034 b
210210
211211
212212 HB2046- 6 -LRB103 05014 RLC 51034 b HB2046 - 6 - LRB103 05014 RLC 51034 b
213213 HB2046 - 6 - LRB103 05014 RLC 51034 b
214214 1 per the provisions outlined in subsection (g) and (h)
215215 2 below;
216216 3 confidential prescription record information collected under
217217 4 Sections 316 and 321 (now repealed) that identifies vendors or
218218 5 practitioners, or both, who are prescribing or dispensing
219219 6 large quantities of Schedule II, III, IV, or V controlled
220220 7 substances outside the scope of their practice, pharmacy, or
221221 8 business, as determined by the Advisory Committee created by
222222 9 Section 320.
223223 10 (f-5) In accordance with a confidentiality agreement
224224 11 entered into with the Department, a medical director, or a
225225 12 public health administrator and their delegated analysts, of a
226226 13 county or municipal health department or the Department of
227227 14 Public Health shall have access to data from the system for any
228228 15 of the following purposes:
229229 16 (1) developing education programs or public health
230230 17 interventions relating to prescribing trends and
231231 18 controlled substance use; or
232232 19 (2) conducting analyses and publish reports on
233233 20 prescribing trends in their respective jurisdictions.
234234 21 At a minimum, the confidentiality agreement entered into
235235 22 with the Department shall:
236236 23 (i) prohibit analysis and reports produced under
237237 24 subparagraph (2) from including information that
238238 25 identifies, by name, license, or address, any
239239 26 practitioner, dispenser, ultimate user, or other person
240240
241241
242242
243243
244244
245245 HB2046 - 6 - LRB103 05014 RLC 51034 b
246246
247247
248248 HB2046- 7 -LRB103 05014 RLC 51034 b HB2046 - 7 - LRB103 05014 RLC 51034 b
249249 HB2046 - 7 - LRB103 05014 RLC 51034 b
250250 1 administering a controlled substance; and
251251 2 (ii) specify the appropriate technical and physical
252252 3 safeguards that the county or municipal health department
253253 4 must implement to ensure the privacy and security of data
254254 5 obtained from the system. The data from the system shall
255255 6 not be admissible as evidence, nor discoverable in any
256256 7 action of any kind in any court or before any tribunal,
257257 8 board, agency, or person. The disclosure of any such
258258 9 information or data, whether proper or improper, shall not
259259 10 waive or have any effect upon its confidentiality,
260260 11 non-discoverability, or non-admissibility.
261261 12 (g) The information described in subsection (f) may not be
262262 13 released until it has been reviewed by an employee of the
263263 14 Department who is licensed as a prescriber or a dispenser and
264264 15 until that employee has certified that further investigation
265265 16 is warranted. However, failure to comply with this subsection
266266 17 (g) does not invalidate the use of any evidence that is
267267 18 otherwise admissible in a proceeding described in subsection
268268 19 (h).
269269 20 (h) An investigator or a law enforcement officer receiving
270270 21 confidential information under subsection (c), (d), or (f) may
271271 22 disclose the information to a law enforcement officer or an
272272 23 attorney for the office of the Attorney General for use as
273273 24 evidence in the following:
274274 25 (1) A proceeding under any State or federal law that
275275 26 involves a controlled substance.
276276
277277
278278
279279
280280
281281 HB2046 - 7 - LRB103 05014 RLC 51034 b
282282
283283
284284 HB2046- 8 -LRB103 05014 RLC 51034 b HB2046 - 8 - LRB103 05014 RLC 51034 b
285285 HB2046 - 8 - LRB103 05014 RLC 51034 b
286286 1 (2) A criminal proceeding or a proceeding in juvenile
287287 2 court that involves a controlled substance.
288288 3 (i) The Department may compile statistical reports from
289289 4 the information described in subsection (a). The reports must
290290 5 not include information that identifies, by name, license or
291291 6 address, any practitioner, dispenser, ultimate user, or other
292292 7 person administering a controlled substance.
293293 8 (j) Based upon federal, initial and maintenance funding, a
294294 9 prescriber and dispenser inquiry system shall be developed to
295295 10 assist the health care community in its goal of effective
296296 11 clinical practice and to prevent patients from diverting or
297297 12 abusing medications.
298298 13 (1) An inquirer shall have read-only access to a
299299 14 stand-alone database which shall contain records for the
300300 15 previous 12 months.
301301 16 (2) Dispensers may, upon positive and secure
302302 17 identification, make an inquiry on a patient or customer
303303 18 solely for a medical purpose as delineated within the
304304 19 federal HIPAA law.
305305 20 (3) The Department shall provide a one-to-one secure
306306 21 link and encrypted software necessary to establish the
307307 22 link between an inquirer and the Department. Technical
308308 23 assistance shall also be provided.
309309 24 (4) Written inquiries are acceptable but must include
310310 25 the fee and the requester's Drug Enforcement
311311 26 Administration license number and submitted upon the
312312
313313
314314
315315
316316
317317 HB2046 - 8 - LRB103 05014 RLC 51034 b
318318
319319
320320 HB2046- 9 -LRB103 05014 RLC 51034 b HB2046 - 9 - LRB103 05014 RLC 51034 b
321321 HB2046 - 9 - LRB103 05014 RLC 51034 b
322322 1 requester's business stationery.
323323 2 (5) As directed by the Prescription Monitoring Program
324324 3 Advisory Committee and the Clinical Director for the
325325 4 Prescription Monitoring Program, aggregate data that does
326326 5 not indicate any prescriber, practitioner, dispenser, or
327327 6 patient may be used for clinical studies.
328328 7 (6) Tracking analysis shall be established and used
329329 8 per administrative rule.
330330 9 (7) Nothing in this Act or Illinois law shall be
331331 10 construed to require a prescriber or dispenser to make use
332332 11 of this inquiry system.
333333 12 (8) If there is an adverse outcome because of a
334334 13 prescriber or dispenser making an inquiry, which is
335335 14 initiated in good faith, the prescriber or dispenser shall
336336 15 be held harmless from any civil liability.
337337 16 (k) The Department shall establish, by rule, the process
338338 17 by which to evaluate possible erroneous association of
339339 18 prescriptions to any licensed prescriber or end user of the
340340 19 Illinois Prescription Information Library (PIL).
341341 20 (l) The Prescription Monitoring Program Advisory Committee
342342 21 is authorized to evaluate the need for and method of
343343 22 establishing a patient specific identifier.
344344 23 (m) Patients who identify prescriptions attributed to them
345345 24 that were not obtained by them shall be given access to their
346346 25 personal prescription history pursuant to the validation
347347 26 process as set forth by administrative rule.
348348
349349
350350
351351
352352
353353 HB2046 - 9 - LRB103 05014 RLC 51034 b
354354
355355
356356 HB2046- 10 -LRB103 05014 RLC 51034 b HB2046 - 10 - LRB103 05014 RLC 51034 b
357357 HB2046 - 10 - LRB103 05014 RLC 51034 b
358358 1 (n) The Prescription Monitoring Program is authorized to
359359 2 develop operational push reports to entities with compatible
360360 3 electronic medical records. The process shall be covered
361361 4 within administrative rule established by the Department.
362362 5 (o) Hospital emergency departments and freestanding
363363 6 healthcare facilities providing healthcare to walk-in patients
364364 7 may obtain, for the purpose of improving patient care, a
365365 8 unique identifier for each shift to utilize the PIL system.
366366 9 (p) The Prescription Monitoring Program shall
367367 10 automatically create a log-in to the inquiry system when a
368368 11 prescriber or dispenser obtains or renews his or her
369369 12 controlled substance license. The Department of Financial and
370370 13 Professional Regulation must provide the Prescription
371371 14 Monitoring Program with electronic access to the license
372372 15 information of a prescriber or dispenser to facilitate the
373373 16 creation of this profile. The Prescription Monitoring Program
374374 17 shall send the prescriber or dispenser information regarding
375375 18 the inquiry system, including instructions on how to log into
376376 19 the system, instructions on how to use the system to promote
377377 20 effective clinical practice, and opportunities for continuing
378378 21 education for the prescribing of controlled substances. The
379379 22 Prescription Monitoring Program shall also send to all
380380 23 enrolled prescribers, dispensers, and designees information
381381 24 regarding the unsolicited reports produced pursuant to Section
382382 25 314.5 of this Act.
383383 26 (q) A prescriber or dispenser may authorize a designee to
384384
385385
386386
387387
388388
389389 HB2046 - 10 - LRB103 05014 RLC 51034 b
390390
391391
392392 HB2046- 11 -LRB103 05014 RLC 51034 b HB2046 - 11 - LRB103 05014 RLC 51034 b
393393 HB2046 - 11 - LRB103 05014 RLC 51034 b
394394 1 consult the inquiry system established by the Department under
395395 2 this subsection on his or her behalf, provided that all the
396396 3 following conditions are met:
397397 4 (1) the designee so authorized is employed by the same
398398 5 hospital or health care system; is employed by the same
399399 6 professional practice; or is under contract with such
400400 7 practice, hospital, or health care system;
401401 8 (2) the prescriber or dispenser takes reasonable steps
402402 9 to ensure that such designee is sufficiently competent in
403403 10 the use of the inquiry system;
404404 11 (3) the prescriber or dispenser remains responsible
405405 12 for ensuring that access to the inquiry system by the
406406 13 designee is limited to authorized purposes and occurs in a
407407 14 manner that protects the confidentiality of the
408408 15 information obtained from the inquiry system, and remains
409409 16 responsible for any breach of confidentiality; and
410410 17 (4) the ultimate decision as to whether or not to
411411 18 prescribe or dispense a controlled substance remains with
412412 19 the prescriber or dispenser.
413413 20 The Prescription Monitoring Program shall send to
414414 21 registered designees information regarding the inquiry system,
415415 22 including instructions on how to log onto the system.
416416 23 (r) The Prescription Monitoring Program shall maintain an
417417 24 Internet website in conjunction with its prescriber and
418418 25 dispenser inquiry system. This website shall include, at a
419419 26 minimum, the following information:
420420
421421
422422
423423
424424
425425 HB2046 - 11 - LRB103 05014 RLC 51034 b
426426
427427
428428 HB2046- 12 -LRB103 05014 RLC 51034 b HB2046 - 12 - LRB103 05014 RLC 51034 b
429429 HB2046 - 12 - LRB103 05014 RLC 51034 b
430430 1 (1) current clinical guidelines developed by health
431431 2 care professional organizations on the prescribing of
432432 3 opioids or other controlled substances as determined by
433433 4 the Advisory Committee;
434434 5 (2) accredited continuing education programs related
435435 6 to prescribing of controlled substances;
436436 7 (3) programs or information developed by health care
437437 8 professionals that may be used to assess patients or help
438438 9 ensure compliance with prescriptions;
439439 10 (4) updates from the Food and Drug Administration, the
440440 11 Centers for Disease Control and Prevention, and other
441441 12 public and private organizations which are relevant to
442442 13 prescribing;
443443 14 (5) relevant medical studies related to prescribing;
444444 15 (6) other information regarding the prescription of
445445 16 controlled substances; and
446446 17 (7) information regarding prescription drug disposal
447447 18 events, including take-back programs or other disposal
448448 19 options or events.
449449 20 The content of the Internet website shall be periodically
450450 21 reviewed by the Prescription Monitoring Program Advisory
451451 22 Committee as set forth in Section 320 and updated in
452452 23 accordance with the recommendation of the advisory committee.
453453 24 (s) The Prescription Monitoring Program shall regularly
454454 25 send electronic updates to the registered users of the
455455 26 Program. The Prescription Monitoring Program Advisory
456456
457457
458458
459459
460460
461461 HB2046 - 12 - LRB103 05014 RLC 51034 b
462462
463463
464464 HB2046- 13 -LRB103 05014 RLC 51034 b HB2046 - 13 - LRB103 05014 RLC 51034 b
465465 HB2046 - 13 - LRB103 05014 RLC 51034 b
466466 1 Committee shall review any communications sent to registered
467467 2 users and also make recommendations for communications as set
468468 3 forth in Section 320. These updates shall include the
469469 4 following information:
470470 5 (1) opportunities for accredited continuing education
471471 6 programs related to prescribing of controlled substances;
472472 7 (2) current clinical guidelines developed by health
473473 8 care professional organizations on the prescribing of
474474 9 opioids or other drugs as determined by the Advisory
475475 10 Committee;
476476 11 (3) programs or information developed by health care
477477 12 professionals that may be used to assess patients or help
478478 13 ensure compliance with prescriptions;
479479 14 (4) updates from the Food and Drug Administration, the
480480 15 Centers for Disease Control and Prevention, and other
481481 16 public and private organizations which are relevant to
482482 17 prescribing;
483483 18 (5) relevant medical studies related to prescribing;
484484 19 (6) other information regarding prescribing of
485485 20 controlled substances;
486486 21 (7) information regarding prescription drug disposal
487487 22 events, including take-back programs or other disposal
488488 23 options or events; and
489489 24 (8) reminders that the Prescription Monitoring Program
490490 25 is a useful clinical tool.
491491 26 (t) Notwithstanding any other provision of this Act,
492492
493493
494494
495495
496496
497497 HB2046 - 13 - LRB103 05014 RLC 51034 b
498498
499499
500500 HB2046- 14 -LRB103 05014 RLC 51034 b HB2046 - 14 - LRB103 05014 RLC 51034 b
501501 HB2046 - 14 - LRB103 05014 RLC 51034 b
502502 1 neither the Prescription Monitoring Program nor any other
503503 2 person shall disclose any information in violation of the
504504 3 restrictions and requirements of paragraph (3.5) of subsection
505505 4 (a) of Section 316 as implemented under Public Act 102-527.
506506 5 (Source: P.A. 102-751, eff. 1-1-23.)
507507
508508
509509
510510
511511
512512 HB2046 - 14 - LRB103 05014 RLC 51034 b